TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is under investigation... TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B cell malignancies including chronic lymphocytic leukemia), NCT05280509 (recruiting,...
- Mechanism
- Curator reviewed
TL-895 inhibits bruton tyrosine kinase, an enzyme involved in cancer growth.
- Code names
- TL-895
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with TL-895, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account